Effectiveness and safety of an abacavir/lamivudine + rilpivirine regimen for the treatment of HIV-1 infection in naive patients

Adrian Curran, Jhon Rojas, Alfonso Cabello, Jesús Troya, Arkaitz Imaz, Pere Domingo, Esteban Martinez, Pablo Ryan, Miguel Górgolas, Daniel Podzamczer, Hernando Knobel, Félix Gutié rrez, Esteban Ribera

Research output: Contribution to journalArticleResearchpeer-review

4 Citations (Scopus)

Abstract

© The Author 2016. Objectives: To describe the effectiveness and safety of an abacavir/lamivudine+rilpivirine regimen in naive HIV-1-infected patients, as there is a lack of data with this combination. Methods: This was an observational, retrospective, multicentre study in eight Spanish hospitals. All antiretroviralnaive patients ≥ 18 years old and starting abacavir/lamivudine + rilpivirine were included. Effectiveness (ITT and on-treatment) and safety (adverse events and laboratory parameters) were assessed during follow-up. Values are expressed as n (%) or median (IQR). The Wilcoxon signed-rank test was used to compare baseline and 6 and 12 month values. Results: Eighty-four patients were included [93% males, age=36 (30-45) years]. Time since HIV diagnosis was 12 (4-35) months. Fifty-one per cent of patients had comorbidities. Baseline CD4+ was 425 (340-519) cells/mm3 and baseline HIV-RNAwas 19000 (9500-42000) copies/mL. Median follow-up was 18 (9-22) months; 100%and 68%patients with at least 6 and 12 months, respectively. At 6 and 12 months effectiveness was 94%and 86%by ITT analysis and 96% and 97% by on-treatment analysis. At 12 months, there were significant increases in CD4+ (+262 cell/mm3) and HDL cholesterol (+4 mg/dL) and a significant decrease in the total cholesterol/HDL cholesterol ratio (20.2). There were two (2.4%) virological failures (HIV-RNA 50-100 copies/mL); one patient later achieving virological suppression without changing the treatment. Six patients (7.1%) changed treatment due to reasons other than virological failure or side effects. One patient discontinued treatment due to gastrointestinal complaints attributed to abacavir/lamivudine. Conclusions: Abacavir/lamivudine+rilpivirine was an effective and safe option in a selected group of HIV-1- infected treatment-naive patients.
Original languageEnglish
Pages (from-to)3510-3514
JournalJournal of Antimicrobial Chemotherapy
Volume71
Issue number12
DOIs
Publication statusPublished - 1 Jan 2016

Fingerprint Dive into the research topics of 'Effectiveness and safety of an abacavir/lamivudine + rilpivirine regimen for the treatment of HIV-1 infection in naive patients'. Together they form a unique fingerprint.

Cite this